The trajectory of the erectile dysfunction drug presents a complex Pharma picture for shareholders. While the initial release generated significant gains, the end of its exclusive rights opened the avenue to off-brand competitors, dramatically eroding revenue. This poses a specific challenge for drug manufacturers banking on comparable blockbuster

The legacy of Viagra, and its developer copyright, presents a complex case study for investors. At first a blockbuster drug, producing billions in sales , its intellectual property lapse created a wave of generic competition , significantly diminishing its dominance. While specific firms may attempt to capitalize on related treatments , the present